SpyGlass Pharma, Inc. Common Stock (NASDAQ: SGP) is a Healthcare company (Biotechnology) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
SpyGlass Pharma, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $31.43, SpyGlass Pharma, Inc. Common Stock trades at 5.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -47.5%, return on invested capital of -36.4% and a free cash flow yield of -5.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 15.24. Over the past 52 weeks the share price ranged from $17.06 to $39.92, with a beta of -0.89.
SpyGlass Pharma, Inc. Common Stock does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, SpyGlass Pharma, Inc. Common Stock (SGP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.7% / 30% · Interest income / Revenue 199200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.7% / 33% · Receivables / Mkt Cap (36m) 0.06% / 49% · Interest income / Revenue 199200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.7% / 33.33% · Receivables / Mkt Cap (24m) 0.06% / 33.33% · Interest income / Revenue 199200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.8% / 33.33% · Receivables / Avg Assets (4Q) 0.28% / 33.33% · Interest income / Revenue 199200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 95.3% / 33.33% · (Cash+Recv) / Total Assets 95.6% / 33.33% · Interest income / Revenue 199200000.0% / 5% | Fail |
No. As of September 2026, SpyGlass Pharma, Inc. Common Stock (SGP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. SpyGlass Pharma, Inc. Common Stock is over the AAOIFI limit on Interest income / Revenue.
About 199200000.0% of each dividend: SpyGlass Pharma, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.